Amgen (NASDAQ:AMGN) Price Target Raised to $351.00

Key Points

• Guggenheim raised its price target on Amgen to $351 while keeping a neutral rating, implying roughly a 0.84% downside from the current share price.
• Sell‑side views are mixed: the consensus rating is Hold with a consensus price target of $355.16, while individual targets span about $309 up to $400, reflecting divergent analyst outlooks.
• Fundamentals remain solid—Amgen beat estimates last quarter (EPS $5.29 vs. $4.76; revenue $9.87B vs. $9.46B) and set FY2026 EPS guidance of 21.600–23.000, with a market cap near $190.8B and a P/E around 24.9.

Amgen (NASDAQ:AMGN - Get Free Report) had its target price hoisted by equities research analysts at Guggenheim from $347.00 to $351.00 in a research report issued on Thursday,MarketScreener reports. The brokerage presently has a "neutral" rating on the medical research company's stock. Guggenheim's price objective points to a potential downside of 0.84% from the company's current price.

Several other research analysts also recently weighed in on the stock. Leerink Partners restated a "market perform" rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Wells Fargo & Company upped their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $350.00 target price on shares of Amgen in a research note on Wednesday. Freedom Capital lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Finally, Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an "outperform" rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Hold" and a consensus price target of $355.16.

Amgen Stock Performance

AMGN opened at $353.97 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company's fifty day moving average price is $363.43 and its two-hundred day moving average price is $334.15. Amgen has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a market cap of $190.81 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business's revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts expect that Amgen will post 20.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Amgen

Several institutional investors have recently added to or reduced their stakes in AMGN. Vanguard Group Inc. boosted its position in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp boosted its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company's stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Capital World Investors boosted its position in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company's stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Capital International Investors boosted its position in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock worth $5,414,296,000 after purchasing an additional 282,219 shares during the period. Finally, Geode Capital Management LLC boosted its position in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Institutional investors own 76.50% of the company's stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase III win — Amgen’s subcutaneous TEPEZZA matched IV efficacy and offers faster, potentially more accessible dosing for thyroid eye disease, supporting revenue expansion prospects. AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
• Positive Sentiment: TEPEZZA on‑body injector data — Phase 3 results for an on‑body injector showed strong efficacy and safety versus IV, suggesting at‑home administration that could broaden uptake amid growing competition. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Analyst upside — RBC raised its price target to $370 and kept an outperform view, signaling increased sell‑side conviction that helps justify the rally. Royal Bank Of Canada Increases Amgen NASDAQ: AMGN Price Target to $370.00
• Positive Sentiment: Competitive positioning — Several analyst notes and commentaries argue Amgen’s TEPEZZA data leaves rivals (notably Viridian) on the defensive, reinforcing Amgen’s lead in thyroid eye disease. Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen
• Neutral Sentiment: Cantor Fitzgerald reiteration — Cantor Fitzgerald reaffirmed a neutral rating with a $350 target, reflecting a balanced view on near‑term upside versus longer‑term LT potential. Benzinga coverage of Cantor Fitzgerald rating
• Neutral Sentiment: Investor interest & value angle — Multiple outlets note increased search/attention and highlight Amgen’s value characteristics, keeping it on watchlists for income/value investors. Here's Why Amgen (AMGN) is a Strong Value Stock
• Negative Sentiment: Morgan Stanley Hold — Morgan Stanley maintained a Hold and set a $309 price target, flagging limited near‑term upside despite acknowledging longer‑term AI/innovation potential; this is a restraint on consensus bullishness. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.